MA54292A - Méthodes de traitement d'un lymphome folliculaire - Google Patents
Méthodes de traitement d'un lymphome folliculaireInfo
- Publication number
- MA54292A MA54292A MA054292A MA54292A MA54292A MA 54292 A MA54292 A MA 54292A MA 054292 A MA054292 A MA 054292A MA 54292 A MA54292 A MA 54292A MA 54292 A MA54292 A MA 54292A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- follicular lymphoma
- treating follicular
- treating
- lymphoma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862773678P | 2018-11-30 | 2018-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA54292A true MA54292A (fr) | 2021-10-06 |
Family
ID=68966021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA054292A MA54292A (fr) | 2018-11-30 | 2019-11-26 | Méthodes de traitement d'un lymphome folliculaire |
Country Status (15)
Country | Link |
---|---|
US (1) | US20200171034A1 (fr) |
EP (1) | EP3886992A1 (fr) |
JP (1) | JP2022513666A (fr) |
KR (1) | KR20210097160A (fr) |
CN (1) | CN113164782A (fr) |
AU (1) | AU2019388899A1 (fr) |
BR (1) | BR112021009978A2 (fr) |
CA (1) | CA3120960A1 (fr) |
EA (1) | EA202191509A1 (fr) |
IL (1) | IL283365A (fr) |
MA (1) | MA54292A (fr) |
MX (1) | MX2021006368A (fr) |
PH (1) | PH12021551140A1 (fr) |
SG (1) | SG11202105309YA (fr) |
WO (1) | WO2020112761A1 (fr) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2908375A1 (fr) * | 2013-04-08 | 2014-10-16 | Pharmacyclics Llc | Combinaison therapeutique a base d'ibrutinib |
KR20160013204A (ko) * | 2013-05-30 | 2016-02-03 | 인피니티 파마슈티칼스, 인코포레이티드 | Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료 |
BR112017001677A2 (pt) * | 2014-08-01 | 2018-07-17 | Pharmacyclics Llc | biomarcadores para predizer resposta de dlbcl ao tratamento com um inibidor de btk |
US20180223368A1 (en) * | 2015-03-18 | 2018-08-09 | Memorial Sloan Ketteting Cancer Center | Methods for diagnosing and treating follicular lymphoma |
PL3892302T3 (pl) * | 2015-04-06 | 2024-03-11 | Janssen Pharmaceutica Nv | Kompozycje zawierające ibrutynib |
WO2017087947A2 (fr) * | 2015-11-19 | 2017-05-26 | Pharmacyclics Llc | Méthode de traitement d'un lymphome folliculaire avec un inhibiteur de tyrosine kinase de bruton |
-
2019
- 2019-11-26 JP JP2021530872A patent/JP2022513666A/ja not_active Ceased
- 2019-11-26 MX MX2021006368A patent/MX2021006368A/es unknown
- 2019-11-26 BR BR112021009978-6A patent/BR112021009978A2/pt unknown
- 2019-11-26 KR KR1020217020004A patent/KR20210097160A/ko active Search and Examination
- 2019-11-26 MA MA054292A patent/MA54292A/fr unknown
- 2019-11-26 CN CN201980078851.9A patent/CN113164782A/zh active Pending
- 2019-11-26 EP EP19824085.5A patent/EP3886992A1/fr not_active Withdrawn
- 2019-11-26 CA CA3120960A patent/CA3120960A1/fr active Pending
- 2019-11-26 SG SG11202105309YA patent/SG11202105309YA/en unknown
- 2019-11-26 WO PCT/US2019/063234 patent/WO2020112761A1/fr unknown
- 2019-11-26 US US16/696,092 patent/US20200171034A1/en active Pending
- 2019-11-26 EA EA202191509A patent/EA202191509A1/ru unknown
- 2019-11-26 AU AU2019388899A patent/AU2019388899A1/en active Pending
-
2021
- 2021-05-19 PH PH12021551140A patent/PH12021551140A1/en unknown
- 2021-05-23 IL IL283365A patent/IL283365A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3886992A1 (fr) | 2021-10-06 |
AU2019388899A1 (en) | 2021-06-10 |
IL283365A (en) | 2021-07-29 |
WO2020112761A1 (fr) | 2020-06-04 |
MX2021006368A (es) | 2021-10-13 |
SG11202105309YA (en) | 2021-06-29 |
EA202191509A1 (ru) | 2021-10-26 |
CN113164782A (zh) | 2021-07-23 |
KR20210097160A (ko) | 2021-08-06 |
US20200171034A1 (en) | 2020-06-04 |
CA3120960A1 (fr) | 2020-06-04 |
BR112021009978A2 (pt) | 2021-08-17 |
PH12021551140A1 (en) | 2021-10-25 |
JP2022513666A (ja) | 2022-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA46954A (fr) | Méthodes de traitement d'états inflammatoires | |
MA51631A (fr) | Anticorps anti-pd1 et méthodes de traitement | |
MA45192A (fr) | Traitement d'association | |
MA52371A (fr) | Méthodes de traitement d'infections dues aux coronaviridae | |
MA46102A (fr) | Composés de tétracycline et méthodes de traitement | |
MA56212A (fr) | Compositions et méthodes de traitement du cancer | |
MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
MA46481A (fr) | Compositions d'oligonucléotides et méthodes associées | |
MA53506A (fr) | Méthodes de traitement du cancer avec des inhibiteurs de pd-l1 à petites molécules | |
MA50264A (fr) | Méthodes de traitement des infections de type hépatite b | |
MA44083A (fr) | Composés de biarylmonobactame pour le traitement d'infections bactériennes | |
MA40867A (fr) | Méthodes pour le traitement d'infections virales à filoviridae | |
MA47719A (fr) | Esketamine pour le traitement de la dépression | |
MA53329A (fr) | Méthodes de traitement de l'épilepsie | |
MA47504A (fr) | Composés et méthodes de traitement de l'angiocholite biliaire primitive | |
MA49576A (fr) | Compositions et méthodes pour le traitement d'infections fongiques | |
MA48730A (fr) | Compositions et méthodes de traitement de synucléinopathies | |
MA54860A (fr) | Méthodes de traitement du myélome multiple | |
MA46353A (fr) | Méthodes de traitement de l'infertilité féminine | |
MA53873A (fr) | Compositions et procédés pour le traitement de la presbytie | |
MA52216A (fr) | Méthodes de traitement de la colite ulcéreuse | |
MA43230A (fr) | Méthodes et compositions pour le traitement d'une épidermolyse bulleuse | |
MA51788A (fr) | Substances et méthodes pour traiter des hémoglobinopathies | |
MA53741A (fr) | Procédés de traitement de troubles myéloprolifératifs | |
MA51678A (fr) | Méthodes de traitement de l'amyotrophie musculaire |